Abbisko Therapeutics

2256 · HKEX

Public Market Listing

2256HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Abbisko Therapeutics are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
FGFR2 / FGFR3Small molecule
Non-Small Cell Lung CancerAchondroplasia
Phase 2
PD-1/PD-L1 interactionSmall molecule
Non-Small Cell Lung Cancer
Phase 1
EGFR exon 20 insertionSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
LumipodlinPhase 2Non-Small Cell Lung Cancer With EGFR Mutation
Est. primary completion 2027-12-30 · NCT06668103 · CT.gov ↗
What to watch
2028 (2)
December 2028 (2)
LavengratinibPhase 1/2Achondroplasia
Est. primary completion 2028-12-15 · NCT07297875 · CT.gov ↗
What to watch
LumipodlinPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2028-12-30 · NCT07164170 · CT.gov ↗
What to watch
2029 (2)
November 2029 (1)
Lumipodlin + LavengratinibPhase 2HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
Est. primary completion 2029-11-30 · NCT06632262 · CT.gov ↗
What to watch
December 2029 (1)
LumipodlinPhase 2Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Est. primary completion 2029-12-31 · NCT07710612 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$85M$71M$286M—report ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$70M$63M——report ↗
2023-FY———$61Mreport ↗
2022-FY———$74Mreport ↗